Ontario Teachers Pension Plan Board bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,833 shares of the biopharmaceutical company’s stock, valued at approximately $274,000.
Other large investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its position in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the last quarter. Quent Capital LLC raised its position in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in shares of Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 12,513 shares during the period. GAMMA Investing LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. Finally, V Square Quantitative Management LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. 92.97% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of analysts have recently commented on ALNY shares. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an “equal weight” rating in a research report on Tuesday, June 25th. Chardan Capital restated a “buy” rating and set a $225.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. HC Wainwright reiterated a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Needham & Company LLC lifted their price target on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Finally, Barclays boosted their price objective on shares of Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 25th. Eight equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $256.73.
Alnylam Pharmaceuticals Price Performance
Shares of ALNY stock traded up $2.16 on Tuesday, hitting $237.75. The stock had a trading volume of 68,381 shares, compared to its average volume of 883,560. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $263.73. The stock’s 50 day moving average is $192.03 and its 200-day moving average is $171.27.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. The firm’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same period last year, the company posted ($1.40) earnings per share. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.99 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, Director Amy W. Schulman sold 21,700 shares of the stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Amy W. Schulman sold 21,700 shares of the stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the transaction, the director now owns 136 shares of the company’s stock, valued at approximately $30,013.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 74,450 shares of company stock valued at $15,287,984. Company insiders own 1.50% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
See Also
- Five stocks we like better than Alnylam Pharmaceuticals
- Top Biotech Stocks: Exploring Innovation Opportunities
- ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
- 3 Fintech Stocks With Good 2021 Prospects
- Leading Beverage Company’s Stock Bubbles Higher: Rally Ahead
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Can This Meme Stock Stage One Last Rally?
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.